



EXPRESS MAIL NO.: EV 335 856 295 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Schneider and Jamal

Confirmation No.: 1583

Application No.: 09/305,084

Group Art Unit: 1642

Filed: May 4, 1999

Examiner: A. Harris

For: Cancer Treatment With Endothelin  
Receptor Antagonists

Attorney Docket No.: 5914-080-999

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §1.56 AND §1.97**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 and §1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to the references C01-C09 listed on the attached form PTO-1449 entitled "List of References Cited by Applicant". Copies of references C01-C09 are submitted herewith.

Identification of the listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. No admission is made that the information cited in this Supplemental Information Disclosure Statement is, or is considered to be, material to patentability nor is it a representation that a search has been made according to 37 C.F.R. § 1.97(g) and § 1.97 (h).

#  
20  
KD  
8-12-03

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Submission of this Supplemental Information Disclosure Statement is after the mailing date of the first Office Action on the merits, therefore, pursuant to 37 C.F.R.

§ 1.97(c), an estimated fee of **\$180.00** is due for the filing of this Disclosure. Please charge the required fee, including any deficiencies in the amount estimated to be due, to Pennie & Edmonds LLP Deposit Account No. 16-1150. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date: July 25, 2003

Laura A. Coruzzi 30,742  
Laura A. Coruzzi (Reg. No.)

By: Jacqueline Benn 43,492  
Jacqueline Benn (Reg. No.)

**PENNIE & EDMONDS** LLP  
1155 Avenue of the Americas  
New York, New York 10036-2711  
Phone: (212) 790-9090



## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

5914-080-999

APPLICATION NO

09/305,084

APPLICANT

Schneider and Jamal

FILING DATE

May 4, 1999

GROUP

1642

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C01	Adner et al., 1994, "Human endothelin ET <sub>A</sub> receptor antisense oligodeoxynucleotides inhibit endothelin-1 evoked vasoconstriction", <i>Eur. J. Pharm.</i> 261:281-284.
C02	Barber et al., 1996, "Chronic increases in blood flow upregulate endothelin-B receptors in arterial smooth muscle", <i>Am. J. Physiol.</i> 270:H65-H71.
C03	Battistini and Dussault, 1998, "Blocking of the endothelin system: the development of receptor antagonists", <i>Pul. Pharm. Therap.</i> 11:97-112.
C04	Chan et al., 1998, "The discovery and structure-activity relationships of nonpeptide, low molecular weight antagonists selective for the endothelin ET <sub>B</sub> receptor", <i>Bioorganic &amp; Medicinal Chemistry</i> 6:2301-2316.
C05	Davenport and Battistini, 2002, "Classification of endothelin receptors and antagonists in clinical development", <i>Clinical Science</i> 103:1S-3S.
C06	D'Orléans-Juste et al., 1997, "DNA antisense strategies in the study of receptors for vasoactive peptides, and of growth and wound-healing factors", <i>Molec. Cell. Biochemistry</i> 172:199-211.
C07	Douglas, 1997, "Clinical development of endothelin receptor antagonists", <i>TIPS</i> 18:408-412.
C08	Mederski et al., 1999, "Benzofuro[3,2-b] Pyridines as mixed ET <sub>A</sub> /ET <sub>B</sub> and selective ET <sub>B</sub> endothelin receptor antagonists", <i>Bioorg. Med. Chem. Lett.</i> 9:619-622.
C09	Ninomiya et al., 1998, "Paracrine endothelin signaling in the control of basal cell proliferation in guinea pig tracheal epithelium", <i>J. Pharmacol. Exp. Therap.</i> 286:469-480.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.